Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography

Ballantyne, Christie M.; Raichlen, Joel S.; Nicholls, Stephen J.; Erbel, Raimund; Tardif, Jean‐Claude; Brener, Sorin J.; Cain, Valerie A.; Nissen, Steven E.

doi:10.1161/circulationaha.108.773747

Cited by 186 publications

(50 citation statements)

References 30 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings with the plaque-scoring method are in agreement with previous studies that showed a beneficial effect of statin therapy on changes in plaque burden over time [17][18][19][20][25][26][27][28][29] ; however, these studies used more expensive and complex imaging modalities to demonstrate a treatment effect. Corti et al used MRI to demonstrate a dose-independent decrease in carotid and aortic plaque burden and an increase in the luminal area after 2 years of simvastatin therapy 27,28) .…”

Section: Discussionsupporting

confidence: 91%

“…In addition, the ASTEROID trial evaluated the effect of rosuvastatin on coronary atherosclerosis. After 2 years of treatment, the median atheroma volume in the most diseased 10-mm subsegment decreased by 9.1% by IVUS 18) , and quantitative coronary angiography showed a significant reduction of coronary stenoses 26) . Also, the JAPAN-ACS study showed that the use MeanMaxPS had progressed when the end-of-study MeanMaxPS was higher than the baseline MeanMaxPS To convert HDL-C and LDL-C from mmol/L to mg/dL, multiply by 38.6.…”

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

The Use of Plaque Score Measurements to Assess Changes in Atherosclerotic Plaque Burden Induced by Lipid-Lowering Therapy Over Time: The METEOR Study

Peters

Doğan

Meijer

et al. 2011

JAT

Self Cite

View full text Add to dashboard Cite

Aim:To evaluate whether plaque scoring measurements are able to track changes in atherosclerotic plaque burden over time and to study whether this is affected by lipid-lowering therapy. Methods: Data used were from METEOR (Measuring Effects on Intima-Media Thickness: an Evaluation Of Rosuvastatin), a randomized controlled trial of rosuvastatin 40 mg among 984 low-risk patients with modest carotid intima-media thickening (CIMT). In this analysis, duplicate ultrasound images from 12 carotid sites were collected at the baseline and end of the study from 495 European patients and were evaluated for plaque presence and severity. Plaques were scored from near and far walls of the 12 sites (0 none; 1 minimal; 2 moderate; 3 severe) and plaque scores (PS) were combined into two summary measures for each examination. The MeanMaxPS is the mean over the 12 carotid sites of the maximum score at each site and the MaxMaxPS reflects the most severe lesion at any site.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 94%

The Use of Plaque Score Measurements to Assess Changes in Atherosclerotic Plaque Burden Induced by Lipid-Lowering Therapy Over Time: The METEOR Study

Peters

Doğan

Meijer

et al. 2011

JAT

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is reported that the seasonal variation in serum LDL cholesterol levels may play an important role in the seasonal incidence of CVD events 17,18) . In this study, LDL cholesterol levels were significantly higher in winter than in summer, but the LDL-HDL ratio, which is a strong predictor of atherosclerosis 19,20) , was comparable in both seasons. Further studies are needed to clarify its clinical significance with CVD events.…”

Section: Discussioncontrasting

confidence: 55%

Seasonal Variation in Serum Lipid Levels in Japanese Workers

Kamezaki

Sonoda

Tomotsune

et al. 2010

JAT

View full text Add to dashboard Cite

show abstract

“…A similar analysis was performed in the ASTEROID trial 125 , which assessed the effects of 2 years of therapy with 40 mg/day rosuvastatin on coronary atherosclerosis measured with both IVUS and QCA. Rosuvastatin reduced low-density lipoprotein cholesterol by 53.3% to 61.1±20.3 mg/dL and increased high-density lipoprotein cholesterol by 13.8% to 48.3±12.4 mg/dL.…”

Section: Correlation Between Ivus and Cimtmentioning

confidence: 99%

Métodos por imagem da aterosclerose em estudos de progressão/regressão: marcador substituto ou janela direta para o processo patológico da aterosclerose?

Schoenhagen¹,

Tuzcu²

2008

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

SummaryCAD remains a major global cause of morbidity and mortality. Comprehensive drug development programs of novel pharmacological treatment strategies frequently utilize traditional mortality/morbidity endpoints studies and additional surrogate endpoints trials. This parallel approach allows an assessment of efficacy several years in advance of the availability of data from clinical endpoint trials. Several atherosclerosis imaging markers have been introduced into these drug-development strategies, including angiography, carotid ultrasound, IVUS, MRI, and CT. This review will discuss the current status of atherosclerosis imaging as an endpoint in progression/regression trials, with an emphasis on evidence-based data. In addition to a discussion of the results of individual imaging modalities, the emerging data comparing different modalities and approaches are presented.

show abstract

Effect of Rosuvastatin Therapy on Coronary Artery Stenoses Assessed by Quantitative Coronary Angiography

Cited by 186 publications

References 30 publications

The Use of Plaque Score Measurements to Assess Changes in Atherosclerotic Plaque Burden Induced by Lipid-Lowering Therapy Over Time: The METEOR Study

The Use of Plaque Score Measurements to Assess Changes in Atherosclerotic Plaque Burden Induced by Lipid-Lowering Therapy Over Time: The METEOR Study

Seasonal Variation in Serum Lipid Levels in Japanese Workers

Métodos por imagem da aterosclerose em estudos de progressão/regressão: marcador substituto ou janela direta para o processo patológico da aterosclerose?

Contact Info

Product

Resources

About